黄芪颗粒联合贝那普利治疗扩张型心肌病合并心力衰竭的临床疗效  

Clinical efficacy of Huangqi granule combined with benazepril in the treatment of dilated cardiomyopathy complicated with heart failure

作　　者：陈勇鹏[1] 王银波 王博东 CHEN Yong-peng;WANG Yin-bo;WANG Bo-dong(Jiexi County Second People＇ s Hospital （Mianhu Overseas Chinese Hospital）, Jieyang 515438, China)

机构地区：[1]揭西县第二人民医院(原棉湖华侨医院),515438

出　　处：《中国现代药物应用》2018年第9期1-3,共3页Chinese Journal of Modern Drug Application

摘　　要：目的观察黄芪颗粒联合贝那普利治疗扩张型心肌病合并心力衰竭的临床疗效。方法 46例扩张型心肌病合并心力衰竭患者,随机分为治疗组和对照组,每组23例。治疗组在予以利尿剂的基础上口服黄芪颗粒联合贝那普利,对照组在予以利尿剂的基础上口服贝那普利,连续观察3个月,观察比较两组患者临床治疗效果。结果治疗后,两组患者血压、心率、左心室射血分数(LVEF)、N-末端脑钠肽前体(NT-pro BNP)及6 min步行距离均较治疗前有所改善,且治疗组明显优于对照组,差异具有统计学意义(P<0.05)。治疗组总有效率为91.30%,对照组为60.87%,两组总有效率比较差异具有统计学意义(P<0.05)。治疗组因心力衰竭再住院率为4.35%,低于对照组的30.43%,差异具有统计学意义(P<0.05)。两组患者用药副作用情况比较差异无统计学意义(P>0.05)。结论黄芪颗粒联合贝那普利治疗扩张型心肌病合并心力衰竭临床疗效确切,明显改善患者心功能,提高治疗效果,值得推广。Objective To observe the clinical efficacy of Huangqi granule combined with benazepril in the treatment of dilated cardiomyopathy complicated with heart failure. Methods A total of 46 patients with dilated cardiomyopathy complicated with heart failure were randomly divided into treatment group and control group, with 23 cases in each group. The treatment group received oral Huangqi granule combined with benazepril on the basis of diuretic, and the control group received oral benazepril on the basis of diuretic. After 3 months of continuous observation, the clinical treatment effect in two groups was observed and compared. Results After treatment, both groups had obviously better blood pressure, heart rate, left ventricular ejection fraction （LVEF）, N terminal pro-brain natriuretic peptide （NT-proBNP） and 6 min walking distance than before treatment, and the treatment group was obviously better than the control group. Their difference was statistically significant （P〈0.05）. After 3 months of treatment, the treatment group had total effective rate as 91.30%, which was 60.87% in the control group. Both groups had statistically significant difference in total effective rate （P〈0.05）. The treatment group had lower re-hospitalization rate due to heart failure as 4.35% than 30.43% in the control group, and the difference was statistically significant （P〈0.05）. Both groups had no statistically significant difference in side effects of medication （P〉0.05）. Conclusion Combination of Huangqi granule and benazepril shows affirmative clinical efficacy in treating dilated cardiomyopathy complicated with heart failure, and obviously improve the cardiac function and treatment effect. It is worthy of promotion.

关 键 词：黄芪颗粒 贝那普利 扩张型心肌病 临床疗效 

分 类 号：R541.6[医药卫生—心血管疾病] R542.2[医药卫生—内科学]